What is Emulait?
Founded in 2019 and headquartered in Las Vegas, Emulait operates at the intersection of health-tech and consumer goods. The company has developed a sophisticated feeding system that utilizes 3D scanning and FDA-approved medical-grade materials to replicate the physiological experience of breastfeeding. With seven patented technologies and four years of rigorous research, Emulait addresses a critical pain point for parents by bridging the gap between breast and bottle. Its market position is defined by a commitment to clinical precision, aiming to standardize high-fidelity feeding solutions that prioritize infant comfort and maternal health outcomes.
How much funding has Emulait raised?
Emulait has raised a total of $14M across 2 funding rounds:
Series A
$11M
Private Equity
$3M
Series A (2023): $11M, investors not publicly disclosed
Private Equity (2025): $3M, investors not publicly disclosed
Key Investors in Emulait
Emulait
Undisclosed investor participating in the funding round.
Emulait
Undisclosed investor participating in the funding round.
Emulait
Undisclosed investor participating in the funding round.
What's next for Emulait?
With this major strategic investment, Emulait is well-positioned to scale its manufacturing capabilities and expand its global distribution footprint. The company's roadmap likely involves deepening its R&D efforts to further refine its biometric feeding technology while exploring new product lines within the infant wellness ecosystem. As the firm transitions into a more mature phase of its lifecycle, the focus will shift toward capturing a larger share of the premium baby care market and establishing long-term partnerships with healthcare providers. This capital deployment will be instrumental in sustaining its competitive advantage and driving long-term value for stakeholders in the rapidly evolving health-tech sector.
See full Emulait company page
